The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
define soon ... ;)
TW/ Captain
Can’t argue - we have had no sales of note, we don’t even know how many cassettes we are manufacturing.
If we only end up with the £374M contract and we can’t sell what is a very good antigen test into the 440M market for home use then the share price will still rerate upwards
If we don’t win/ sell anything then it’s going to be very messy
I believe we will secure the £374M contract and sell into EU and am hoping USA as well, hence I am holding - 80% chance that’s my personal opinion if I was trying to measure from known data
If you think there is a risk above 50% you may have to take a view, either sell / watch from sidelines, but one of the above or all 3 come off then Omega gets a serious upwards rerate and the Offer price won’t be 51p.
Looks like we have found a support level around the 50 to 55p range, holders feel something is coming
That’s the risk / reward for us all, sit it out or take a chance
I am taking a measured risk and holding for news of contracts / sales opportunities
We will soon find out which was the best move/ position
Good luck to all this coming week
twatcher - spot on post.
ODX can still come good..but they need to get the discussions finished and start producing. if they had been producing 3 months ago when these talks started they might have been eyeing up an additional gov contract by now.....or in any case a lot sooner.
i still don't believe in their ability to sell in EU or USA. they haven't sold in china/africa/uk - so I don't see any indication of a good sales team
I don't care if it is mud standard and not even 1/2 as good as Innova, just like Innova aren't one bit worried since they got their gazzillions orders of Uk gov, and apparently uk gov wasn't all that concerned either.
ODX is a commercial, listed company, owned by shareholders. A manufacturer that has not announced orders, production, stock or output, is only a virtual manufacturer. Growth in capacity was a fantastic acheivement, but only because the growth was supposed to be underpinned by increasing orders, i.e. the capacity was being full utilised along the way. I'd suggest there is plenty of evidence to conclude that capacity has not been fully utilised since the start of Nov.
They've needed orders all year. For most of that time we've had the happy clappers saying there are NDAs, "3B antibody tests neede", or they are stockpiling, or they are producing 2M a week every week, "the train is leaving" "get on board the rocket", sure how could they not, all those employees, and lets not forget the lorry that dropped of a peice of equipment, that's as good as 2M a week right there.
I think even the most happy of happy clappers are finally coming to the cold realisation that they have been fundamentally producing nothing. All that busy busy busy we have been fed from twitter, that implies production, isn't. You'll note none of the recent RNSs refer to production. Anything of substance has to be RNS-ed. The Twitter account seems to be aimed at those that are reasonably easily strung along. ODX have a history of not backing up twitter hyperbole with reality.
Being honest I don't care if mologic is considered gold std or not...just need some sales.
Innova was pony standard as we all know and they got £3b...
There will be demand for lft for at least 6 months as we go into the peak season and the gov are still issuing free tests. Question is do odx want some of it ? If they do then they need to conclude these talks because otherwise some one else will gladly take our share..as demonstrated by the three recent contracts on bidstacks.
Ball is in your court Colin...do you want to sell or not? Or you can make excuses about other key markets.
GAZZA and Big Kev must have filled their vacancy
Until then it's LFTs for ease of use and speed - so we can sort of get back to something loosely resembling "normal" - and any positive LFT results then have to take a PCR test (so we can track variants) and are sent along to a PCR lab, perhaps the new high-throughput one Yourgene Health just landed a contract for.
it's not my definition, your definition or Bill Gates for that matter. It's what is universally known by the 'experts' and it most certainly is not lft. When the likes of the NHS adopt lft as their gold standard then that's when it will be confirmed, not by anyone here.
I very much think lft has it's place and if it could sequence too, then it would be unstoppable, until then?
So easy
It's high-accuracy, validated by loads of authorities world-wide and it's literally cheaper than chips. What's your definition of gold standard?!
BTW: I agree about PCR still having it's place. We need them to track variants.
my god! this board should be named the paranoia board! lol.
djf, I hold shares here. Just saying that pcr testing is not being scrapped totally as some seem to think.
Senza. lft of any sort is not ''gold standard'' sorry to p iss on your chips, just saying! Just because many think Mologic's test is pretty good doesn't make it officially 'gold standard, does it?
Bakky must be related to GAZZA so obvious
Oh contrair, just about any authority that's tested the Mologic test, thinks it's one of the best. And it’s been tested a heck of a lot, by multiple authorities around the world, due to FIND.
The Mologic test is quite likely the most validated, high-accuracy, lateral-flow test on Earth.
Bakky is clearly not an LFT fan. Another basher to try and kill sentiment here. Stick to Genedrive buddy.
Medusa given distribution contract for Avacta test for nhs use only, professional use ie self use for nhs.
Symbo1...not arguing but where does your info come from that Avacta have bagged the NHS?
I too believe by the way that we will ramp up capacity here to more than 2m a week when required...soon I hope!
Hardly makes it the ''gold standard'' though does it??
FIND and Bill & Melinda Gates Foundation are quite big fans of the Mologic test.
''As lft’s are supposedly now Uk gold standard'' really! who says so?
Looks like Avacta have bagged the nhs use requirement. Looks like ODX etc being directed for domestic use, probably with domestic antibody as well. Picture forming.
As lft’s are supposedly now Uk gold standard and highly accurate, each positive will be followed up by a pcr test and variants will be checked for at this stage.
My only concern, as it always has been is meeting demand. We will no doubt sell all we can make but demand will far outstrip our capability. Let’s hope , when news is released that we have improved the 2m per week benchmark.